News

Trans-Tasman drug developer AFT Pharmaceuticals is targeting lucrative niche diseases its Big Pharma rivals have ignored. ...
On this week’s Out of the Blue, the boys dive into the positives and negatives for every Big Ten team ahead of the 2025 ...